Issue Date: August 24, 2006
Life After Zocor
Second-quarter financial results from U.S. pharmaceutical companies gave an early glimpse into life after Zocor, the blockbuster cholesterol drug from Merck that lost patent protection with just a week left in the quarter.
The news was bright for some—companies with newer drugs appear to be well—insulated from generic competition-and far from the dark scenario feared for Pfizer, whose cholesterol agent Lipitor was expected to be the most affected by patients switching to generic . . .
To view the rest of this content, please log in with your ACS ID.
Table: Drug Companies
Stronger earnings put U.S. company profit margins above European firms'.
Table is available as an image file.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society